Eris Lifesciences Ltd · NSE:ERIS
Eris Lifesciences — Q2 FY22 Earnings Presentation
18 slides from Eris Lifesciences's earnings presentation, Oct 29, 2021
Slide 1: Stock exchange filing cover letter: Investor Presentation
Date: 29th October, 2021 To To BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza Dalal Street Bandra Kurla Complex Mumbai- 400001 Bandra (E) Mumbai-400051 Security Code: 540596 Symbol: ERIS SUBJECT: INVESTOR PRESENTATION Dear Sir/Madam, Pursuant to the req
Slide 2: Q2 FY22 and H1 FY22 Investor Presentation
Q2 FY 22 and H1 FY 22 INVESTOR PRESENTATION 29th October 2021 1
Slide 3: Financial Highlights – Q2 FY22 and H1 FY22
FINANCIAL HIGHLIGHTS – Q2 FY 22 and H1 FY 22 Q2 FY 22 H1 FY 22 INR mn INR mn INR mn INR mn 3,597 1,398 7,089 2,663 9.0% 12.1% 13.8% 16.4% Op Revenue yoy growth EBITDA yoy growth Op Revenue yoy growth EBITDA yoy growth INR mn INR mn 1,184 2,251 9.9% 14.4% PAT yoy growth PAT yoy growth • Favourable pr
Slide 4: Eris Has Maintained Market-Leading Growth From Pre-Covid Levels
ERIS HAS MAINTAINED MARKET-LEADING GROWTH FROM PRE-COVID LEVELS Eris has outperformed the 21.2% IPM by 390 bps since 19.0% pre-Covid times 16.3% 14.9% 13.5% 12.6% 12.2% 11.6% 10.5% 10.4% 8.3% IPM exl. Covid IPCA ARISTO MACLEODS MANKIND EMC URE TORRENT ERIS LS INTAS ALEMBIC CIPLA % Acute molecules Th
Slide 5: Sustained Outperformance in Core Therapies From Pre-Covid Levels
SUSTAINED OUTPERFORMANCE IN CORE THERAPIES FROM PRE-COVID LEVELS GROWTH OF ERIS Vs. MARKET OVER THE LAST EIGHT QUARTERS ORAL ANTI-DIABETES CARDIOLOGY 12.2% over IPM 2.3% over IPM 12.1% 19.1% 9.8% KEY PRODUCT ADDITIONS 6.9% IPM Eris IPM Eris VMN CNS 3.2% over IPM 12.4% 7.5% over IPM 15.6% 9.2% 8.1% I
Slide 6: Eris Continues to Outperform in Chronic Therapies
ERIS CONTINUES TO OUTPERFORM IN CHRONIC THERAPIES DESPITE SIGNIFICANT SLOWDOWN IN CHRONIC/ SUBCHRONIC IN Q2 FY22 Eris grew at 11.4% yoy in Q2 FY 22 vs. IPM growth of 14.6%; outperformed the market in Chronic (66% of Eris Revenue) Q1 FY 22 • Eris performance vs. Market in Q1 and Q2 by Therapy Areas Q
Slide 7: Eris Maintains High Prescription Ranking Among Doctor Specialties
ERIS MAINTAINS HIGH PRESCRIPTION RANKING AMONG DOCTOR SPECIALTIES Eris Prescription Ranking* among Doctor Specialties 3 4 3 DIABETOLOGISTS CARDIOLOGISTS NEUROLOGISTS 4 CONSULTING 6 GASTROENTEROLOGISTS PHYSICIANS Source: SMSRC MAT Aug 2021 * Rank in Represented Market 6
Slide 8: Strong Performance in Latest Generation Diabetes Products
STRONG PERFORMANCE IN LATEST GENERATION DIABETES PRODUCTS Crossed INR 25 crores revenues in first year of launch (Launched in Oct 2020) Continues to Rank #1 among 40+ Gx versions of Dapagliflozin Monthly sales run-rate scaled up 4x (to ~ Rs 3 crore pm) in one year since launch Crossed INR 54+ crore
Slide 9: Power Brands Continue to Have Leading Presence in Core Therapies (1/2)
POWER BRANDS CONTINUE TO HAVE LEADING PRESENCE IN CORE THERAPIES (1/2) Therapy wide presence in Oral Diabetes Care with power brands holding high ranks in Newer-generation fast-growing molecules Sulfonylurea rank 6 in the ≈4,700 cr Glimepiride and combinations market Glimisave MV rank 2 in Glimepiri
Slide 10: Power Brands Continue to Have Leading Presence in Core Therapies (2/2)
POWER BRANDS CONTINUE TO HAVE LEADING PRESENCE IN CORE THERAPIES (2/2) High rank in Anti-Hypertensives: the largest segment of Cardiac Care rank 5 in the ≈3,700 cr Telmisartan and combinations market Eritel CH rank 4 in Telmisartan + Chlorthalidone market Eritel LN rank 2 in Telmisartan + Cilnidipin
Slide 11: Eris Bags Prestigious Award for Digital Transformation
ERIS BAGS PRESTIGIOUS AWARD FOR DIGITAL TRANSFORMATION Eris Lifesciences has been chosen as “The Innovator” in Digital Transformation Event Conducted by Seamless transition to Digital - 3,200+ Webinars covering 46,000+ Clinicians since the start of the pandemic Demonstrated strong resilience in the
Slide 12: Eris Continues to Execute on Growth Drivers (1/2)
ERIS CONTINUES TO EXECUTE ON GROWTH DRIVERS (1/2) Expansion of power-brands’ 1 • Our business model of building strong and sustainable brands has enabled us to maintain franchise our growth trajectory during the pandemic periods (Wave 1 as well as Wave 2) when MR- Doctor interactions were severely c
Slide 13: Eris Continues to Execute on Growth Drivers (2/2)
ERIS CONTINUES TO EXECUTE ON GROWTH DRIVERS (2/2) Expansion of physician • We are working on significantly expanding our coverage of Specialists and Consulting 3 coverage Physicians over the next 5 years 4 Therapeutic Diversification • We are investing in diversification opportunities in high-growth
Slide 14: Q2 FY22 and H1 FY22 - Standalone Income Statement
Q2 FY 22 AND H1 FY22 - STANDALONE INCOME STATEMENT Standalone Q2 FY 22 H1 FY 22 INR Millions Q2 FY 22 Q2 FY 21 H1 FY 22 H1 FY 21 yoy Gr % yoy Gr % Sale of Products 3,161 2,984 5.9% 6,164 5,545 11.2% • Operating Revenue grew by 6.4% yoy in Q2 FY 22 and Other Operating Income 66 50 31.2% 125 104 20.7%
Slide 15: Q2 FY22 and H1 FY22 - Consolidated Income Statement
Q2 FY 22 AND H1 FY22 - CONSOLIDATED INCOME STATEMENT Consolidated Q2 FY 22 H1 FY 22 Q2 FY 22 Q2 FY 21 H1 FY 22 H1 FY 21 INR Millions yoy Gr % yoy Gr % Branded Formulation Sales Sale of Products 3,533 3,253 8.6% 6,970 6,133 13.6% Q2 FY 22 H1 FY 21 INR Millions Q2 FY 22 Q2 FY 21 H1 FY 22 H1 FY 21 Othe
Slide 16: Shareholder Profile
SHAREHOLDER PROFILE Shareholding of Promoters and Top 15 Institutional Investors Others, As on As on As on FPIs, 0.49% Name of Shareholder 30-Sep-21 30-Jun-21 31-Mar-21 13.60% 761* 708* 605* Promoters 52.68% 52.69% 54.13% 1 ChrysCapital (Emerald Investment Limited) 5.50% 5.51% 5.51% 2 UTI Mutual Fun
Slide 17: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward- looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and the underlying assumptions
Slide 18: Thank You
THANK YOU KRUTI RAVAL INVESTOR RELATIONS kruti@erislifesciences.com 17